Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Blood (2024) 144 (9): 955–963.

https://doi.org/10.1182/blood.2024024041

Published: 2024

Includes: Supplemental data

Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2023) 142 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2023-189850

Published: 2023

Journal Articles

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Blood (2023) 142 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2023-189537

Published: 2023

Journal Articles

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Blood (2023) 142 (Supplement 1): 340.

https://doi.org/10.1182/blood-2023-190209

Published: 2023

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

Dominik Dytfeld, Binod Dhakal, Mounzer Agha, Salomon Manier, Michel Delforge, Steven Kuppens, Salma Afifi, William Deraedt, Agne Taraseviciute-Morris, Jordan M. Schecter, Jane Gilbert, Fevzi Yalniz, Erika Florendo, Lida Pacaud, Vania Hungria, Saad Z. Usmani, Maria-Victoria Mateos

Blood (2021) 138 (Supplement 1): 1835.

https://doi.org/10.1182/blood-2021-146210

Published: 2021

Journal Articles

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Blood (2021) 138 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2021-146188

Published: 2021

Journal Articles

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Blood (2020) 136 (22): 2513–2523.

https://doi.org/10.1182/blood.2020007522

Published: 2020

Includes: Supplemental data

Journal Articles

Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-143003

Published: 2020

Journal Articles

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Ola Landgren, MD PhD, Michel Attal, MD PhD, Dickran Kazandjian, MD, Murielle Roussel, MD, Jagoda K. Jasielec, MD, Dominik Dytfeld, Aparna Anderson, Tara Kervin, Karim Iskander, Khalid Mezzi, Tim Welliver, Akeem Yusuf, PhD BPharm, Andrzej Jakubowiak, MD PhD

Blood (2019) 134 (Supplement_1): 1891.

https://doi.org/10.1182/blood-2019-127076

Published: 2019

Journal Articles

Preemptive Daratumumab Therapy for Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma: Rationale and Design of the Polish Myeloma Consortium Predator Study

Krzysztof Jamroziak, Krzysztof Giannopoulos, Tomasz Wrobel, MD PhD, Adam Nowicki, Bartosz Pula, Norbert Grząśko, Justyna Rybka, Paweł J. Robak, MD, Agnieszka Druzd-Sitek, Adam Walter-Croneck, Katarzyna Brzeźniakiewicz-Janus, MDPhD, Jarosław Czyż, Krzysztof Warzocha, Dominik Dytfeld

Blood (2017) 130 (Supplement 1): 5404.

https://doi.org/10.1182/blood.V130.Suppl_1.5404.5404

Published: 2017

Journal Articles

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Blood (2017) 130 (Supplement 1): 4533.

https://doi.org/10.1182/blood.V130.Suppl_1.4533.4533

Published: 2017

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

Journal Articles

Comparative Proteomic Profiling of Sera from Patients with Refractory Multiple Myeloma Reveals Pathways and Biomarkers Predicting Response to Bortezomib-Based Therapy

Dominik Dytfeld, MD PhD, Magdalena Luczak, PhD, Tomasz Szczepaniak, MD, Anna Przybylowicz-Chalecka, Msc, Blazej Ratajczak, MSc, Joanna Czerwinska-Rybak, MSc, Adam Nowicki, MD PhD, Monika Joks, MD PhD, Andrzej Jakubowiak, MD PhD, Mieczyslaw Komarnicki, MD PhD

Blood (2016) 128 (22): 2092.

https://doi.org/10.1182/blood.V128.22.2092.2092

Published: 2016

Journal Articles

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Todd Zimmerman, MD, Noopur S. Raje, Ravi Vij, Donna Reece, MD, Jesus G. Berdeja, MD, Leonor A Stephens, PhD, Kathryn McDonnell, Cara A. Rosenbaum, MD, Jagoda Jasielec, MD, Paul G Richardson, MD, Sandeep Gurbuxani, Jennifer Nam, Erica Severson, Brittany D. Wolfe, MMS, PA-C, Shaun Rosebeck, PhD, Andrew Stefka, Dominik Dytfeld, MD PhD, Kent Griffith, PhD, Andrzej Jakubowiak, MDPhD

Blood (2016) 128 (22): 675.

https://doi.org/10.1182/blood.V128.22.675.675

Published: 2016

Journal Articles

Comparative Proteomic Profiling of Refractory/Relapsed Multiple Myeloma Patient Plasma Cells Reveals Biomarkers and Pathways Involved in Bortezomib-Based-Therapy Resistance

Dominik Dytfeld, MD PhD, Magdalena Luczak, PhD, Anna Przybylowicz-Chalecka, Msc, Blazej Ratajczak, MSc, Adam Nowicki, MD, Joanna Czerwinska-Rybak, MSc, Monika Joks, MD PhD, Tomasz Szczepaniak, MD PhD, Bochenek Maciej, Andrzej Jakubowiak, MD PhD, Mieczyslaw Komarnicki, MD PhD

Blood (2015) 126 (23): 2986.

https://doi.org/10.1182/blood.V126.23.2986.2986

Published: 2015

Journal Articles

Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

Jagoda Jasielec, Dominik Dytfeld, Kent A. Griffith, Kathryn McDonnell, Daniel Lebovic, Malathi Kandarpa, PhD, Tara Anderson, Melissa Mietzel, Malek Faham, Liana Lee, Joan Levy, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark Kaminski, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2127.

https://doi.org/10.1182/blood.V124.21.2127.2127

Published: 2014

Journal Articles

Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Martin van Vliet, PhD, Jagoda Jasielec, MD, Dominik Dytfeld, MD PhD, Ravi Vij, MD, Belinda Dumee, BSc, Lizanne Bosman, BSc, Leonie C.M. deBest, MSc, Mattina Alonge, MS, Shaun Rosebeck, PhD, Malathi Kandarpa, PhD, Kathryn McDonnell, BS, Kent A. Griffith, Erik H van Beers, PhD, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2141.

https://doi.org/10.1182/blood.V124.21.2141.2141

Published: 2014

Journal Articles

Predictive and Prognostic Significance of Immunohistochemical Markers and Blood Absolute Lymphocyte Count in Diffuse Large B-Cell Lymphoma in Rituximab Era: A Polish Lymphoma Research Group (PLRG) Multicenter Retrospective Analysis

Anna Czyz, Monika Joks, Joanna E Drozd-Sokolowska, Wanda Knopinska-Posluszny, Magdalena Zawartko, Ewa Mizera-Nyczak, Dominik Dytfeld, Barbara Zdziarska, Wiktor-Wieslaw Jedrzejczak, Mieczyslaw Komarnicki

Blood (2014) 124 (21): 5413.

https://doi.org/10.1182/blood.V124.21.5413.5413

Published: 2014

Journal Articles

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Kent A. Griffith, MPH, MS, Kathryn McDonnell, BS, Daniel Lebovic, MD, Malathi Kandarpa, PhD, David H. Vesole, MD, PhD, Sundar Jagannath, MD, Melissa A. Mietzel, MS CCRP, Ravi Vij, MD, Malek Faham, MD, PhD, Liana Lee, BS, Erik H. van Beers, PhD, Martin H. van Vliet, PhD, Joan Levy, PhD, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark S. Kaminski, MD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 3220.

https://doi.org/10.1182/blood.V122.21.3220.3220

Published: 2013

Journal Articles

Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM)

Shaun Rosebeck, PhD, Malathi Kandarpa, PhD, Mattina M. Alonge, Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Sean P Maxwell, Stephanie J Kraftson, Dilara McCauley, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 279.

https://doi.org/10.1182/blood.V122.21.279.279

Published: 2013

NARROW

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Preemptive Daratumumab Therapy for Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma: Rationale and Design of the Polish Myeloma Consortium Predator Study

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Comparative Proteomic Profiling of Sera from Patients with Refractory Multiple Myeloma Reveals Pathways and Biomarkers Predicting Response to Bortezomib-Based Therapy

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Comparative Proteomic Profiling of Refractory/Relapsed Multiple Myeloma Patient Plasma Cells Reveals Biomarkers and Pathways Involved in Bortezomib-Based-Therapy Resistance

Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Predictive and Prognostic Significance of Immunohistochemical Markers and Blood Absolute Lymphocyte Count in Diffuse Large B-Cell Lymphoma in Rituximab Era: A Polish Lymphoma Research Group (PLRG) Multicenter Retrospective Analysis

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only